Patent ID: 9040520
Filing Date: 2015-05-26
Classification: A61K,A61P,C07B,C07D

Abstract:
1. A stable pharmaceutically acceptable salt of noribogaine ansolvate, which is amorphous or is a crystalline hydrochloride salt having an X-ray powder diffraction pattern comprising peaks at 11.6±0.2° 2θ, 12.1±0.2° 2θ, 13.5±0.2° 2θ, 13.9±0.2° 2θ, 14.9±0.2° 2θ, 15.7±0.2° 2θ, 17.1±0.2° 2θ, 17.9±0.2° 2θ, 18.3±0.2° 2θ, 19.8±0.2° 2θ, 20.8±0.2° , 21.0±0.2° 2θ, 21.9±0.2° 2θ, 22.8±0.2° 2θ, 23.3±0.2° 2θ, 24.9±0.2° 2θ, 25.9±0.2° , 26.4±0.2° 2θ, 29.3±0.2° 2θ and 29.8±0.2° 2θ as shown in is a crystalline sulfate salt having an X-ray powder diffraction pattern comprising peaks at 8.5±0.2° 2θ, 11.4±0.2° 2θ, 12.0±0.2° 2θ, 13.3±0.2° 2θ, 15.4±0.2° 2θ, 16.6±0.2° , 17.2±0.2° 2θ, 18.3±0.2° 2θ, 20.6±0.2° 2θ, 21.0±0.2° 2θ and 21.5±0.2° 2θ as shown in when analyzed using CuKα X-ray radiation.